Thank you Irene Fernandez-Ruiz for this great piece of commentary in @natrevcardiol.nature.com on the IVORY trial published in @natmed.nature.com Main paper can be found here: rdcu.be/eX8W3 @ziadmallat.bsky.social @18fdg.bsky.social @vpd-hlri.bsky.social @medcambridge.bsky.social

Nature Reviews Cardiology@natrevcardiol.nature.com · 7mo ago

New online! Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes #CardioSky

New online! Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes #CardioSky

Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes

Nature Reviews Cardiology, Published online: 22 January 2026; doi:10.1038/s41569-026-01256-0Treatment with low-dose IL-2 increases regulatory T cell numbers and reduces arterial inflammation in patients with an acute coronary syndrome and residual systemic inflammation compared with placebo, according to findings from the IVORY trial.

dlvr.it

In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo. https://www.nature.com/articles/s41591-025-04090-y

Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀 Main paper: rdcu.be/eX8W3 Commentary: rdcu.be/eYyG6 @jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social

Thank you @vpd-hlri.bsky.social for the shout-out. Original article here: rdcu.be/eX8W3

VPD Heart & Lung Research Institute@vpd-hlri.bsky.social · 7mo ago

IVORY trial results published! 🫀 Early results show reduced artery inflammation and a trend towards fewer future heart events. www.cam.ac.uk/research/news/targeting-the-immune-system-could-prevent-future-heart-attacks-clinical-trial-suggests

The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3 This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a ⬆️ Regulatory T cells ⬇️ Arterial inflammation 🔥 ⬇️ trend in adverse cardiovascular outcomes ❤️‍🔥 at 2 years

PAPER ALERT: The IVORY trial published in Nature Medicine last week: rdcu.be/eX8W3 @ziadmallat.bsky.social @vpd-hlri.bsky.social @nihr.bsky.social @cuh.nhs.uk @royalpapworth.bsky.social @inserm.fr @parcc-inserm.bsky.social @medcambridge.bsky.social @rouchelles.bsky.social @jc403.bsky.social

Amazing work by @rouchelles.bsky.social & Co. Prions of this team! Nature Medicine: rdcu.be/eX8W3

@rouchelles.bsky.social · 7mo ago

Delighted to share that the results of the IVORY trial were published in Nature Medicine: rdcu.be/eX8W3 This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.

Thank you @danieljdrucker.bsky.social for highlighting our work. This may be a game changer! Nature Medicine: rdcu.be/eX8W3

Daniel Drucker@danieljdrucker.bsky.social · 7mo ago

After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation. www.nature.com/articles/s41...

Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation. Learn More: www.nature.com/articles/s41...

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine

In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...

nature.com

Original article: rdcu.be/eX8W3

Inserm@inserm.fr · 7mo ago

Dans un essai clinique de phase 2, une équipe de l'Inserm montre l’efficacité d’un nouveau traitement pour réduire l'inflammation chronique ou résiduelle qui peut être observée après un syndrome coronaire aigu (SCA). Lire le communiqué : presse.inserm.fr/syndrome-cor...